Tjoung-Won Park-Simon
Overview
Explore the profile of Tjoung-Won Park-Simon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
4997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wockel A, Park-Simon T, Korfel A, Raab K, Tesch H
Breast Cancer Res Treat
. 2025 Mar;
PMID: 40087230
No abstract available.
2.
Wockel A, Park-Simon T, Korfel A, Raab K, Tesch H
Breast Cancer Res Treat
. 2025 Feb;
PMID: 39976865
Purpose: This study aimed to identify preferences of patients with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR + /HER2-) early breast cancer (EBC) related to adjuvant...
3.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
4.
Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, Grischke E, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941823
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced...
5.
Haberle L, Erber R, Gass P, Hein A, Niklos M, Volz B, et al.
Breast Cancer Res
. 2025 Jan;
27(1):13.
PMID: 39856787
Background: Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) after neoadjuvant chemotherapy. Individualized pCR prediction based on clinical information available at...
6.
Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla M, et al.
Breast Cancer Res
. 2024 Dec;
26(1):189.
PMID: 39734228
Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk...
7.
Ruckhaberle E, Schmidt M, Welt A, Harbeck N, Wockel A, Gluz O, et al.
Geburtshilfe Frauenheilkd
. 2024 Sep;
84(9):813-836.
PMID: 39229634
Endocrine-based combination therapy with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitors) is currently the first-line therapy of choice for patients with hormone receptor-positive (HR+) and human...
8.
Davidson A, Michailidou K, Parsons M, Fortuno C, Bolla M, Wang Q, et al.
Am J Hum Genet
. 2024 Aug;
111(9):2059-2069.
PMID: 39096911
Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines....
9.
Sperlich S, Noeres D, Holthausen-Markou S, Park-Simon T, Sahiti E, Geyer S
Support Care Cancer
. 2024 Aug;
32(8):566.
PMID: 39093481
Purpose: This study analyzes levels of social participation in patients with breast cancer on average 5 years following primary surgery as compared to women in the general population. In addition,...
10.
Thill M, Janni W, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, et al.
Breast Care (Basel)
. 2024 Jun;
19(3):183-191.
PMID: 38894953
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally...